{"content":"<li class=\"n-box-item date-title\" data-end=\"1505188799\" data-start=\"1505102400\" data-txt=\"Monday, December 23, 2019\">Monday, September 11, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3294760\" data-ts=\"1505173608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294760-media-companies-band-together-for-sports-free-streaming\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Media companies band together for sports-free streaming</a></h4><ul>     <li>A number of \"loner\" networks in the new streaming era are banding together along with their parent companies to offer a new direct service <a href=\"https://www.wsj.com/articles/coming-soon-a-streaming-tv-bundle-for-people-who-dont-like-sports-1505170652\" target=\"_blank\">counterprogrammed for those who don't care for sports</a>, <i>The Wall Street Journal</i> reports.</li>   <li>A soft launch is weeks away for a service from Discovery Communication (<a href=\"http://seekingalpha.com/symbol/DISCA\" target=\"_blank\">DISCA</a> <font color='red'>-2.1%</font>), Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='red'>-1.5%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='red'>-0.3%</font>), AMC Networks (<a href=\"http://seekingalpha.com/symbol/AMCX\" target=\"_blank\">AMCX</a> <font color='red'>-0.7%</font>), Scripps Networks Interactive (<a href=\"http://seekingalpha.com/symbol/SNI\" target=\"_blank\">SNI</a> <font color='red'>-0.3%</font>) and A&amp;E (co-owned by Walt Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) and Hearst).</li>     <li>Subscriptions will be less than $20 a month -- helped along by the fact that the service will save on what has become very high costs for live sports programming.</li>     <li>The exact list of networks is still to be determined, but sources say the parent companies all expect their core channels will be part of the service.</li>     <li>It will be branded Philo after the college-campus streaming specialist that will be powering it (itself named for TV inventor Philo Farnsworth).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294760\" data-linked=\"Media companies band together for sports-free streaming\" data-tweet=\"$VIA $VIA $VIAB - Media companies band together for sports-free streaming https://seekingalpha.com/news/3294760-media-companies-band-together-for-sports-free-streaming?source=tweet\" data-url=\"https://seekingalpha.com/news/3294760-media-companies-band-together-for-sports-free-streaming\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294759\" data-ts=\"1505173008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHTR\" target=\"_blank\">CHTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294759-charter-prices-2b-in-new-senior-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charter prices $2B in new senior debt</a></h4><ul>   <li>Charter Communications (<a href=\"http://seekingalpha.com/symbol/CHTR\" target=\"_blank\">CHTR</a> <font color='red'>-3%</font>) has <a href=\"https://seekingalpha.com/pr/16937187-charter-prices-2_0-billion-senior-secured-notes\" target=\"_blank\">priced $2B in senior debt</a>, in a pair of series.</li>    <li>Through subsidiaries Charter Communications Operating LLC and Charter Communications Operating Capital, it's offering $1.25B in 4.2% senior secured notes due March 2028 (issued at 99.757% of face value), and $750M in 5.375% senior secured notes due 2047 (issued at 98.969% of face value).</li>    <li>As with recent sales, proceeds go to general purposes which could include buybacks of Charter common stock.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294759\" data-linked=\"Charter prices $2B in new senior debt\" data-tweet=\"$CHTR - Charter prices $2B in new senior debt https://seekingalpha.com/news/3294759-charter-prices-2b-in-new-senior-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3294759-charter-prices-2b-in-new-senior-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294758\" data-ts=\"1505172075\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWN\" target=\"_blank\">SWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294758-southwestern-energy-prices-1_15b-in-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southwestern Energy prices $1.15B in debt</a></h4><ul>   <li>Southwestern Energy (<a href=\"http://seekingalpha.com/symbol/SWN\" target=\"_blank\">SWN</a> <font color='green'>+4.4%</font>) has priced an <a href=\"https://seekingalpha.com/pr/16937167-southwestern-energy-announces-pricing-public-offering-1_15-billion-senior-notes\" target=\"_blank\">offering of $1.15B in debt</a> in two tranches.</li>    <li>The company's offering $650M in 7.5% senior unsecured notes due 2026, and a $500M series of 7.75% senior unsecured notes due 2027.</li>    <li>Both series will be sold at 100% of face value.</li>    <li>Net proceeds are expected at about $1.133B; SWN will use $327M to repay a 2015 term loan, and the rest along with cash on hand to fund tender offers (for any and all of its 4.05% senior notes due 2020, and $100M of each of 4.1% senior notes due 2022 and 4.95% senior notes due 2025).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294758\" data-linked=\"Southwestern Energy prices $1.15B in debt\" data-tweet=\"$SWN - Southwestern Energy prices $1.15B in debt https://seekingalpha.com/news/3294758-southwestern-energy-prices-1_15b-in-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3294758-southwestern-energy-prices-1_15b-in-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294753\" data-ts=\"1505166944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTR\" target=\"_blank\">NTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294753-agrium-potash-get-ok-for-merger-from-canada\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agrium, Potash get OK for merger from Canada</a></h4><ul>   <li>Agrium (<a href=\"http://seekingalpha.com/symbol/AGU\" target=\"_blank\">AGU</a> <font color='green'>+2.8%</font>) and Potash (<a href=\"http://seekingalpha.com/symbol/POT\" target=\"_blank\">POT</a> <font color='green'>+3%</font>) have gotten an unconditional <a href=\"https://seekingalpha.com/pr/16937123-agrium-potashcorp-receive-unconditional-canadian-regulatory-clearance-merger\" target=\"_blank\">OK from the Canadian Competition Bureau</a> for their merger via a no-action letter today.</li>    <li>The two had previously gotten unconditional approvals in Russia and Brazil, while it awaits results in the U.S., China and India.</li>    <li>The CCB says the deal isn't likely to lead to a lessening or prevention of competition in potash, phosphate fertilizers and nitric acid.</li>    <li>The two expect to close the deal and become \"Nutrien\" by the end of Q4.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294753\" data-linked=\"Agrium, Potash get OK for merger from Canada\" data-tweet=\"$NTR - Agrium, Potash get OK for merger from Canada https://seekingalpha.com/news/3294753-agrium-potash-get-ok-for-merger-from-canada?source=tweet\" data-url=\"https://seekingalpha.com/news/3294753-agrium-potash-get-ok-for-merger-from-canada\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294751\" data-ts=\"1505166389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294751-report-western-digital-wins-bid-for-toshiba-chip-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Western Digital wins bid for Toshiba chip unit</a></h4><ul><li><a href=\"https://www.nikkan.co.jp/articles/view/00442700\" target=\"_blank\">According to&nbsp;<em>Nikkan Kogyo</em></a>, a group including Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) has won the bidding for Toshiba's (<a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) chip unit for somewhere around &yen;2T.</li><li>WDC<font color='green'> +3.6%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3294751\" data-linked=\"Report: Western Digital wins bid for Toshiba chip unit\" data-tweet=\"$WDC $WDC $TOSYY - Report: Western Digital wins bid for Toshiba chip unit https://seekingalpha.com/news/3294751-report-western-digital-wins-bid-for-toshiba-chip-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3294751-report-western-digital-wins-bid-for-toshiba-chip-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294750\" data-ts=\"1505166149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294750-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+1.5%</font>. <a href='https://seekingalpha.com/symbol/RGC' title='Regal Entertainment Group'>RGC</a> <font color='green'>+1.3%</font>. <a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a> <font color='green'>+1.2%</font>. <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+1.1%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+1.0%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/LMNR' title='Limoneira'>LMNR</a> <font color='red'>-11.1%</font>. <a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='red'>-8.7%</font>. <a href='https://seekingalpha.com/symbol/BIP' title='Brookfield Infrastructure Partners L.P.'>BIP</a> <font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='red'>-3.4%</font>. <a href='https://seekingalpha.com/symbol/LARK' title='Landmark Bancorp Inc.'>LARK</a> <font color='red'>-3.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294750\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$PVG $RGC $MUX - After Hours Gainers / Losers https://seekingalpha.com/news/3294750-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3294750-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294743\" data-ts=\"1505162732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYPT\" target=\"_blank\">EYPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294743-psivida-fiscal-q4-revenue-up-131-durasert-nda-filing-year-end-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">pSivida fiscal Q4 revenue up 131%; Durasert NDA filing by year-end; shares up 1% after hours</a></h4><ul><li>pSivida (PSDV) <a href=\"https://seekingalpha.com/pr/16937010-psivida-corp-achieves-significant-milestones-throughout-fy-2017-reports-fourth-quarter-fiscal\" target=\"_blank\">fiscal Q4 revenue </a>was $701K, up 130.6%, while net loss narrowed 4.2% to ($6.1M).</li><li>Key fiscal 2018 milestones: File Durasert NDA in U.S. by calendar year-end/early January 2018.</li><li>12-month data readout from three-year Durasert uveitis study and safety results from second Phase 3.</li><li>Report initial 24-week Phase 1 data in knee osteoarthritis.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on higher-than-normal volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294743\" data-linked=\"pSivida fiscal Q4 revenue up 131%; Durasert NDA filing by year-end; shares up 1% after hours\" data-tweet=\"$EYPT - pSivida fiscal Q4 revenue up 131%; Durasert NDA filing by year-end; shares up 1% after hours https://seekingalpha.com/news/3294743-psivida-fiscal-q4-revenue-up-131-durasert-nda-filing-year-end-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3294743-psivida-fiscal-q4-revenue-up-131-durasert-nda-filing-year-end-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294742\" data-ts=\"1505162531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPT\" target=\"_blank\">CPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294742-camden-property-trust-selling-stock-shares-down-1_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Camden Property Trust selling stock; shares down 1.5%</a></h4><ul><li>The company is offering 4.75M common shares. Underwriters Deutsche Bank and JPMorgan have a greenshoe option for another 712.5K shares.</li><li><a href='https://seekingalpha.com/symbol/CPT' title='Camden Property Trust'>CPT</a>&nbsp;<font color='red'>-1.5%</font>&nbsp;after hours</li><li>Source: <a href=\"https://seekingalpha.com/pr/16937089-camden-property-trust-announces-public-offering-common-shares\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294742\" data-linked=\"Camden Property Trust selling stock; shares down 1.5%\" data-tweet=\"$CPT - Camden Property Trust selling stock; shares down 1.5% https://seekingalpha.com/news/3294742-camden-property-trust-selling-stock-shares-down-1_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3294742-camden-property-trust-selling-stock-shares-down-1_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294741\" data-ts=\"1505162099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294741-jefferies-expects-cryptocurrency-demand-to-continue-for-nvidia-amd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies expects cryptocurrency demand to continue for Nvidia, AMD</a></h4><ul><li>        Jefferies thinks cryptocurrency mining will continue to boost chip demand for the long-term even as other analysts express doubts that the wave will continue, according to <a href=\"https://www.cnbc.com/2017/09/11/jefferies-says-cryptocurrency-mining-market-is-strong-for-nvidia-and-amd.html\" target=\"_blank\">CNBC</a>.</li><li>               Jefferies analyst Mark Lipacis thinks the risk of an &ldquo;inventory correction driving material downside is low in the near term.&rdquo;&nbsp;</li><li>               Lipacis expects that the same features making the chips attractive to miners will also translate over to blockchain applications in financial services beyond cryptocurrency.&nbsp;</li><li>               Lipacis reiterates his Buy ratings for Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) and AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) with the price targets of $180 and $19, respectively.&nbsp;</li><li>               Nvidia shares closed today&nbsp;<font color='green'>up 3.24%</font>.&nbsp;</li><li>                  AMD shares closed today&nbsp;<font color='green'>up 2.45%.&nbsp;</font> </li><li>Previously: <a href=\"https://seekingalpha.com/news/3293029-jefferies-analyst-names-top-semiconductor-stocks\" target=\"_blank\">Jefferies analyst names top semiconductor stocks</a> (Aug. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294741\" data-linked=\"Jefferies expects cryptocurrency demand to continue for Nvidia, AMD\" data-tweet=\"$NVDA $NVDA $AMD - Jefferies expects cryptocurrency demand to continue for Nvidia, AMD https://seekingalpha.com/news/3294741-jefferies-expects-cryptocurrency-demand-to-continue-for-nvidia-amd?source=tweet\" data-url=\"https://seekingalpha.com/news/3294741-jefferies-expects-cryptocurrency-demand-to-continue-for-nvidia-amd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294726\" data-ts=\"1505161107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDMO\" target=\"_blank\">CDMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294726-peregrine-fiscal-q1-top-line-up-384-loss-narrows-89-shares-up-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peregrine fiscal Q1 top line up 384%, loss narrows 89%; shares up 4% after hours</a></h4><ul><li>Peregrine Pharmaceuticals (PPHM) <a href=\"https://seekingalpha.com/pr/16937036-peregrine-pharmaceuticals-reports-financial-results-first-quarter-fiscal-year-2018-recent\" target=\"_blank\">fiscal Q1 results</a> ($M): Contract manufacturing revenue: 27.1 (+383.9%).</li><li>Net Loss: (1.2) (+89.2%); Loss/Share: (0.06) (+83.3%).</li><li>Manufacturing backlog: $33M.</li><li><strong>Fiscal 2018</strong> manufacturing revenue guidance: $50M - 55M.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294726\" data-linked=\"Peregrine fiscal Q1 top line up 384%, loss narrows 89%; shares up 4% after hours\" data-tweet=\"$CDMO - Peregrine fiscal Q1 top line up 384%, loss narrows 89%; shares up 4% after hours https://seekingalpha.com/news/3294726-peregrine-fiscal-q1-top-line-up-384-loss-narrows-89-shares-up-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3294726-peregrine-fiscal-q1-top-line-up-384-loss-narrows-89-shares-up-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294716\" data-ts=\"1505160349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294716-portola-pharma-readies-300m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharma readies $300M stock offering</a></h4><ul><li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) <a href=\"https://seekingalpha.com/pr/16937015-portola-pharmaceuticals-announces-proposed-offering-common-stock\" target=\"_blank\">launches </a>a $300M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294716\" data-linked=\"Portola Pharma readies $300M stock offering\" data-tweet=\"$PTLA - Portola Pharma readies $300M stock offering https://seekingalpha.com/news/3294716-portola-pharma-readies-300m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3294716-portola-pharma-readies-300m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294710\" data-ts=\"1505159816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294710-health-insurance-innovations-to-host-investor-call-today-4-30-pm-et\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations to host investor call today at 4:30 pm ET</a></h4><ul><li>Acting quickly to stem the sell-off stoked by SA Contributor Richard Pearson's bearish article, Health Insurance Innovations (<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-21.9%</font>) will host a <a href=\"https://seekingalpha.com/pr/16936982-health-insurance-innovations-inc-schedules-management-update-call\" target=\"_blank\">conference call</a> for investors today at 4:30 pm ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294627-health-insurance-innovations-pressure-bearish-report-sa-contributor-pearson-shares-14-percent\" target=\"_blank\">Health Insurance Innovations under pressure on bearish report from SA Contributor Pearson; shares down 14%</a> (Sept. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294710\" data-linked=\"Health Insurance Innovations to host investor call today at 4:30 pm ET\" data-tweet=\"$HIIQ - Health Insurance Innovations to host investor call today at 4:30 pm ET https://seekingalpha.com/news/3294710-health-insurance-innovations-to-host-investor-call-today-4-30-pm-et?source=tweet\" data-url=\"https://seekingalpha.com/news/3294710-health-insurance-innovations-to-host-investor-call-today-4-30-pm-et\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294706\" data-ts=\"1505158491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIX\" target=\"_blank\">SIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294706-six-flags-and-cedar-fair-break-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Six Flags and Cedar Fair break higher</a></h4><ul>     <li>Six Flags Entertainment (<a href='https://seekingalpha.com/symbol/SIX' title='Six Flags Entertainment Corporation'>SIX</a> <font color='green'>+4.5%</font>) and Cedar Fair (<a href='https://seekingalpha.com/symbol/FUN' title='Cedar Fair, L.P.'>FUN</a> <font color='green'>+2.4%</font>) are recovering from the weakness showed last week in front of the arrival of Hurricane Irma.</li>     <li>Six Flags has a key park in Atlanta and Cedar Fair's Carowinds is in North Carolina, but both companies aren't closely tied to the U.S. Southeast.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294674-seaworld-plus-5-percent-orlando-park-due-open-tomorrow\" target=\"_blank\">SeaWorld +5% with Orlando park due to open tomorrow</a> (Sept. 11)</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3294706\" data-linked=\"Six Flags and Cedar Fair break higher\" data-tweet=\"$SIX $SIX $FUN - Six Flags and Cedar Fair break higher https://seekingalpha.com/news/3294706-six-flags-and-cedar-fair-break-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3294706-six-flags-and-cedar-fair-break-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294705\" data-ts=\"1505158394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYES\" target=\"_blank\">EYES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294705-second-sight-board-member-reports-42-stake-shares-up-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Second Sight board member reports 42% stake, shares up 15%</a></h4><ul><li>Thinly traded nano cap Second Sight Medical (<a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='green'>+14.7%</font>) is up on lower-than-normal volume in response to a <a href=\"https://seekingalpha.com/filing/3694007\" target=\"_blank\">13D filing</a> by board member Gregg Williams disclosing a 42% stake (~26.7M shares) held directly by him or entities controlled by him.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294705\" data-linked=\"Second Sight board member reports 42% stake, shares up 15%\" data-tweet=\"$EYES - Second Sight board member reports 42% stake, shares up 15% https://seekingalpha.com/news/3294705-second-sight-board-member-reports-42-stake-shares-up-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3294705-second-sight-board-member-reports-42-stake-shares-up-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294702\" data-ts=\"1505157786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294702-gold-sheds-last-weeks-advance-risk-appetite-returns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold sheds last week&#39;s advance as risk appetite returns</a></h4><ul><li>Hurricane Irma was way less than feared and North Korea refrained from any more missile tests over the weekend. What more could an equity investor ask for? The Dow, S&amp;P 500, and Nasdaq are all&nbsp;<font color='green'>higher by more than 1%</font>, and the 10-year Treasury yield has spiked 8 basis points to 2.13%.</li><li>Gold's&nbsp;<font color='red'>1.5% decline</font>&nbsp;today brings the price down to its pre-Labor Day level of $1,331 per ounce. <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>&nbsp;<font color='red'>-1.4%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='ETFS Physical Swiss Gold Trust ETF'>SGOL</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/DGL' title='PowerShares DB Gold ETF'>DGL</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/GLDW' title='SPDR Long Dollar Gold Trust ETF'>GLDW</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/GHS' title='REX Gold Hedged S&P 500 ETF'>GHS</a>, <a href='https://seekingalpha.com/symbol/GHE' title='REX Gold Hedged FTSE Emerging Markets ETF'>GHE</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294702\" data-linked=\"Gold sheds last week&#39;s advance as risk appetite returns\" data-tweet=\"$GLD $IAU $PHYS - Gold sheds last week&#39;s advance as risk appetite returns https://seekingalpha.com/news/3294702-gold-sheds-last-weeks-advance-risk-appetite-returns?source=tweet\" data-url=\"https://seekingalpha.com/news/3294702-gold-sheds-last-weeks-advance-risk-appetite-returns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294701\" data-ts=\"1505157627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIMO\" target=\"_blank\">GIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294701-gigamon-leaps-on-reported-purchase-offer-from-elliotts-evergreen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gigamon leaps on reported purchase offer from Elliott&#39;s Evergreen</a></h4><ul>   <li>Gigamon (NYSE:<a href='https://seekingalpha.com/symbol/GIMO' title='Gigamon, Inc.'>GIMO</a>) has spiked in the past few minutes, now <font color='green'>up 4.1%</font>, after Reuters reports that an Elliott Management affiliate has made an offer to buy the company.</li>    <li>Evergreen, the private-equity arm of Elliott, has made the offer, Reuters says quoting sources.</li>    <li>Shares briefly <font color='green'>spiked 12%</font> before immediately retrenching.</li><li>Gigamon has a market cap of about $1.64B.</li><li><strong>Updated:</strong> Evergreen <a href=\"https://www.reuters.com/article/us-gigamon-m-a-elliott/exclusive-elliotts-evergreen-makes-bid-to-buy-gigamon-sources-idUSKCN1BM2GP\" target=\"_blank\">secured financing</a> from two investment banks and recently made a formal bid for the company, Reuters says. A successful bid would mark the first time Elliott's P-E group led an acquisition that the activist side had put into play.</li><li>Evergreen had also taken part in an auction for LifeLock, where Elliott had taken an activist stake, though the company went to Symantec.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294701\" data-linked=\"Gigamon leaps on reported purchase offer from Elliott&#39;s Evergreen\" data-tweet=\"$GIMO - Gigamon leaps on reported purchase offer from Elliott&#39;s Evergreen https://seekingalpha.com/news/3294701-gigamon-leaps-on-reported-purchase-offer-from-elliotts-evergreen?source=tweet\" data-url=\"https://seekingalpha.com/news/3294701-gigamon-leaps-on-reported-purchase-offer-from-elliotts-evergreen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294699\" data-ts=\"1505157098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRCO\" target=\"_blank\">TRCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294699-sinclair-sets-early-renewal-four-cbs-affiliates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinclair sets early renewal with four CBS affiliates</a></h4><ul>   <li>With the FCC poring over its $3.9B deal for Tribune Media (<a href=\"http://seekingalpha.com/symbol/TRCO\" target=\"_blank\">TRCO</a> <font color='red'>-0.4%</font>), Sinclair Broadcast Group (<a href=\"http://seekingalpha.com/symbol/SBGI\" target=\"_blank\">SBGI</a> <font color='red'>-0.9%</font>) has tied up another affiliation deal, setting a <a href=\"https://deadline.com/2017/09/cbs-renews-tv-affiliation-deals-four-sinclair-stations-1202167245/\" target=\"_blank\">multi-year renewal with CBS</a> (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='red'>-1.7%</font>) for outlets that were to expire at 2018's end.</li>    <li>The deal resets affiliation with CBS for Sinclair stations in Cedar Rapids, Iowa; Harlingen, Texas; and Portland, Maine; as well as a Syracuse, N.Y., affiliate covered by a Sinclair joint sales agreement.</li>    <li>The move points the way to an easier renewal of 20 other CBS affiliates at Sinclair.</li>    <li>The renewed stations reach a combined 1.5M homes; Sinclair's CBS stations overall reach 9M homes (about 8% of the country).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294699\" data-linked=\"Sinclair sets early renewal with four CBS affiliates\" data-tweet=\"$TRCO $TRCO $SBGI - Sinclair sets early renewal with four CBS affiliates https://seekingalpha.com/news/3294699-sinclair-sets-early-renewal-four-cbs-affiliates?source=tweet\" data-url=\"https://seekingalpha.com/news/3294699-sinclair-sets-early-renewal-four-cbs-affiliates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294698\" data-ts=\"1505156807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHTR\" target=\"_blank\">CHTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294698-moodys-keeps-stable-outlook-on-charter-debt-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moody&#39;s keeps stable outlook on Charter debt sales</a></h4><ul>    <li>Moody's has <a href=\"https://www.moodys.com/research/Moodys-assigns-Ba1-rating-to-Charter-Communications-proposed-notes-issuance--PR_372461\" target=\"_blank\">given a Ba1 rating</a> to proposed notes from Charter Communications (<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a> <font color='red'>-2.4%</font>), which has been loading up on debt this month, in part to have cash available for buybacks.</li>    <li>The firm is maintaining a Ba2 corporate family rating on Charter, supported by \"the company's large scale and moderate leverage\" even after acquiring Time Warner Cable and Bright House Networks.</li>    <li>Moody's expects Charter's debt-to-EBITDA to stay below 4.5x over its rating horizon, and that Charter will continue to generate positive free cash flow and maintain liquidity.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294698\" data-linked=\"Moody&#39;s keeps stable outlook on Charter debt sales\" data-tweet=\"$CHTR - Moody&#39;s keeps stable outlook on Charter debt sales https://seekingalpha.com/news/3294698-moodys-keeps-stable-outlook-on-charter-debt-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3294698-moodys-keeps-stable-outlook-on-charter-debt-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294696\" data-ts=\"1505156297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294696-vertex-in-red-on-cautious-stat-article-regarding-kalydeco-development-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex in the red on cautious STAT article regarding Kalydeco development; shares down 1%</a></h4><ul><li>Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='red'>-1.2%</font>) slips into the red after being up as much as 2.6%. The culprit appears to be an <a href=\"https://www.statnews.com/2017/09/11/vertex-study-kalydeco/\" target=\"_blank\">article </a>by STAT News' Adam Feuerstein who cites the company's quiet termination of a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02971839?term=ctp-656&amp;rank=3\" target=\"_blank\">Phase 2 clinical trial</a> evaluating a long-acting version of Kalydeco (ivacaftor) in cystic fibrosis patients with CFTR gating mutations. Per ClinicalTrials.gov, the estimated completion was last month.</li><li>The company says development remains on track but apparently is mum on the reason for terminating (or at least not reporting the results) the trial.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294696\" data-linked=\"Vertex in the red on cautious STAT article regarding Kalydeco development; shares down 1%\" data-tweet=\"$VRTX - Vertex in the red on cautious STAT article regarding Kalydeco development; shares down 1% https://seekingalpha.com/news/3294696-vertex-in-red-on-cautious-stat-article-regarding-kalydeco-development-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3294696-vertex-in-red-on-cautious-stat-article-regarding-kalydeco-development-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294694\" data-ts=\"1505156162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294694-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Inc.'>ATOM</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/INVE' title='Identiv, Inc.'>INVE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SMIT' title='Schmitt Industries, Inc.'>SMIT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/XPLR' title='Xplore Technologies Corp.'>XPLR</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294694\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$MARK $VERI $ATOM - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3294694-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294694-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294690\" data-ts=\"1505154731\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FEYE\" target=\"_blank\">FEYE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294690-fireeye-up-after-upgrade-positive-analyst-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FireEye up after upgrade, positive analyst comments</a></h4><ul><li>        FireEye (NASDAQ:<a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a>) shares&nbsp;<font color='green'>up 2.78%</font>&nbsp;after Stephens <a href=\"https://www.streetinsider.com/dr/news.php?id=13281977\" target=\"_blank\">upgrades</a> the stock from Equal Weight to Overweight with a $22 price target.</li><li>               Piper Jaffray also out with <a href=\"https://www.streetinsider.com/dr/news.php?id=13282661\" target=\"_blank\">positive comments</a> on the company saying that the Equifax breach revealed last week is a &ldquo;positive&rdquo; for cyber security stocks FireEye, Proofpoint, and Symantec. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294289-equifax-reports-massive-cyberattack-shares-6-percent-hours\" target=\"_blank\">Equifax reports massive cyberattack; shares down 6% after hours</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294690\" data-linked=\"FireEye up after upgrade, positive analyst comments\" data-tweet=\"$FEYE - FireEye up after upgrade, positive analyst comments https://seekingalpha.com/news/3294690-fireeye-up-after-upgrade-positive-analyst-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3294690-fireeye-up-after-upgrade-positive-analyst-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294682\" data-ts=\"1505152535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABY\" target=\"_blank\">BABY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294682-natus-medical-to-buy-neurosurgery-assets-from-integra-for-47_5m-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natus Medical to buy neurosurgery assets from Integra for $47.5M; shares ahead 8%</a></h4><ul><li>Natus Medical (<a href='https://seekingalpha.com/symbol/BABY' title='Natus Medical Incorporated'>BABY</a> <font color='green'>+8.2%</font>) inks an <a href=\"https://seekingalpha.com/pr/16936278-natus-acquire-neurosurgery-assets-integra-lifesciences-enters-neurosurgery-market\" target=\"_blank\">agreement </a>with Integra LifeSciences Holdings (<a href='https://seekingalpha.com/symbol/IART' title='Integra LifeSciences Holdings Corporation'>IART</a> <font color='green'>+1.8%</font>) to purchase certain of its neurosurgery assets for $47.5M in cash. The business currently generates ~$50M in annual sales.</li><li>Natus will acquire the global Camino ICP monitoring product line, including the San Diego-based manufacturing facility, and the U.S. rights to Integra's fixed pressure shunts, Codman's DURAFORM dural graft implant, standard EVD catheters and CSF collection systems.</li><li>Integra is divesting the assets in order to get the FTC's blessing on its proposed acquisition of Johnson &amp; Johnson's Codman Neurosurgery business.</li><li>Both transactions should close next month. Natus will fund its deal with cash on hand and borrowings under its credit facility.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294682\" data-linked=\"Natus Medical to buy neurosurgery assets from Integra for $47.5M; shares ahead 8%\" data-tweet=\"$BABY $NTUS $IART - Natus Medical to buy neurosurgery assets from Integra for $47.5M; shares ahead 8% https://seekingalpha.com/news/3294682-natus-medical-to-buy-neurosurgery-assets-from-integra-for-47_5m-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3294682-natus-medical-to-buy-neurosurgery-assets-from-integra-for-47_5m-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294681\" data-ts=\"1505152399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPOT\" target=\"_blank\">SPOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294681-raymond-james-hulu-spotify-bundle-needs-to-catch-on-in-media\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James: Hulu/Spotify bundle needs to catch on in media</a></h4><ul>   <li>Raymond James notes that a bundle created for college students by Spotify (MUSIC) and Hulu (<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='red'>-1.6%</font>, <a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>, <a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a> <font color='green'>+0.4%</font>) will likely be at the <a href=\"http://www.barrons.com/articles/expect-more-digital-bundles-from-media-companies-1505143847\" target=\"_blank\">forefront of a trend</a>, with subscription services sprouting like weeds.</li>    <li>The two companies will offer services that would cost $13/month on a stand-alone basis for just $4.99/month together, in a bundling move that's \"frankly overdue\" for media companies, says analyst Justin Patterson.</li>    <li>Fragmentation among subscription media services is growing, and marketing them isn't cheap, he notes. And Spotify and Hulu can add customers through the deal since there's modest overlap for the two among millennials.</li>    <li>Looking at other stocks, he notes Netflix (<a href=\"http://seekingalpha.com/symbol/NFLX\" target=\"_blank\">NFLX</a> <font color='green'>+3%</font>) already struck a deal with T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color='green'>+0.2%</font>) and so technically it's part of a bundle of sorts (not quite a content bundle like Spotify/Hulu), but that Netflix's competitive position is secure. And a relationship with Sirius XM (<a href=\"http://seekingalpha.com/symbol/SIRI\" target=\"_blank\">SIRI</a> <font color='green'>+0.8%</font>) is a potential catalyst for Pandora (<a href=\"http://seekingalpha.com/symbol/P\" target=\"_blank\">P</a> <font color='red'>-2.4%</font>) as customers await possible bundles there.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294681\" data-linked=\"Raymond James: Hulu/Spotify bundle needs to catch on in media\" data-tweet=\"$SPOT $SPOT $CMCSA - Raymond James: Hulu/Spotify bundle needs to catch on in media https://seekingalpha.com/news/3294681-raymond-james-hulu-spotify-bundle-needs-to-catch-on-in-media?source=tweet\" data-url=\"https://seekingalpha.com/news/3294681-raymond-james-hulu-spotify-bundle-needs-to-catch-on-in-media\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294679\" data-ts=\"1505151843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MELI\" target=\"_blank\">MELI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294679-big-pop-for-mercadolibre-after-positive-analyst-note\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big pop for MercadoLibre after positive analyst note</a></h4><ul> <li>MercadoLibre (<a href='https://seekingalpha.com/symbol/MELI' title='MercadoLibre, Inc.'>MELI</a> <font color='green'>+8%</font>) jumps after M Science tips that the e-commerce player's Q3 revenue came in ahead of estimates through the end of August.</li> <li>A free shipping policy from MercadoLibe is helping to boost listings growth.</li> <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294679\" data-linked=\"Big pop for MercadoLibre after positive analyst note\" data-tweet=\"$MELI - Big pop for MercadoLibre after positive analyst note https://seekingalpha.com/news/3294679-big-pop-for-mercadolibre-after-positive-analyst-note?source=tweet\" data-url=\"https://seekingalpha.com/news/3294679-big-pop-for-mercadolibre-after-positive-analyst-note\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294674\" data-ts=\"1505150370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAS\" target=\"_blank\">SEAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294674-seaworldplus-5-orlando-park-due-to-open-tomorrow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SeaWorld +5% with Orlando park due to open tomorrow</a></h4><ul> <li>Shares of SeaWorld Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment Inc.'>SEAS</a>) are <font color='green'>up 4.95%</font> after the company says it can open back up its Orlando theme park tomorrow.</li> <li>Today's move in share price takes SeaWorld back up to where it stood before the Hurricane Irma track started to narrow in on the central part of Florida.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294674\" data-linked=\"SeaWorld +5% with Orlando park due to open tomorrow\" data-tweet=\"$SEAS - SeaWorld +5% with Orlando park due to open tomorrow https://seekingalpha.com/news/3294674-seaworldplus-5-orlando-park-due-to-open-tomorrow?source=tweet\" data-url=\"https://seekingalpha.com/news/3294674-seaworldplus-5-orlando-park-due-to-open-tomorrow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294676\" data-ts=\"1505150125\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294676-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='green'>+17%</font>.<a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/FNHC' title='FedNat Holding Company'>FNHC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/UIHC' title='United Insurance Holdings Corp.'>UIHC</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a> <font color='red'>-6%</font>. WMIH <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294676\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$HRTG $HCI $UVE - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3294676-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294676-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294673\" data-ts=\"1505150010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294673-lithium-producers-party-china-mulls-ban-on-fossil-fuel-vehicles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lithium producers party as China mulls ban on fossil-fuel vehicles</a></h4><ul><li>Among the movers: Albermarle (<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a> <font color='green'>+4.6%</font>), Lithium Corp. (<a href='https://seekingalpha.com/symbol/LTUM' title='Lithium Corporation.'>OTCQB:LTUM</a> <font color='green'>+11.2%</font>),&nbsp;Sociedad Quimica y Minera de Chile (<a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='green'>+7%</font>), FMC Corp. (<a href='https://seekingalpha.com/symbol/FMC' title='FMC Corporation'>FMC</a> <font color='green'>+3%</font>).</li><li>The Global X Lithium ETF (<a href='https://seekingalpha.com/symbol/LIT' title='Global X Lithium ETF'>LIT</a> <font color='green'>+4.8%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294532-china-studying-ban-gas-vehicles\" target=\"_blank\">China studying ban on gas vehicles</a> (Sept. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294673\" data-linked=\"Lithium producers party as China mulls ban on fossil-fuel vehicles\" data-tweet=\"$ALB $ALB $LTUM - Lithium producers party as China mulls ban on fossil-fuel vehicles https://seekingalpha.com/news/3294673-lithium-producers-party-china-mulls-ban-on-fossil-fuel-vehicles?source=tweet\" data-url=\"https://seekingalpha.com/news/3294673-lithium-producers-party-china-mulls-ban-on-fossil-fuel-vehicles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294670\" data-ts=\"1505149240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294670-cymabays-seladelpar-orphan-drug-in-europe-for-primary-biliary-cholangitis-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay&#39;s seladelpar an Orphan Drug in Europe for primary biliary cholangitis; shares up 2%</a></h4><ul><li>The European Medicines Agency's Committee for Orphan Medicinal Products &#40;COMP&#41; <a href=\"https://seekingalpha.com/pr/16936399-cymabay-therapeutics-granted-ema-orphan-drug-designation-seladelpar-treatment-primary-biliary\" target=\"_blank\">recommends </a>the designation of Orphan Drug status for CymaBay Therapeutics' (<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a> <font color='green'>+2.3%</font>) seladelpar for the treatment of primary biliary cholangitis &#40;PBC&#41;, a serious liver disease characterized by the progressive destruction of the bile ducts.</li><li>Among the benefits of Orphan Drug status in the EU is a 10-year period of market exclusivity for the indication, if approved.</li><li>Phase 2-stage seladelpar is a selective, orally active PPAR&delta; agonist that is also in development for the treatment of nonalcoholic steatohepatitis &#40;NASH&#41;.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294670\" data-linked=\"CymaBay&#39;s seladelpar an Orphan Drug in Europe for primary biliary cholangitis; shares up 2%\" data-tweet=\"$CBAY - CymaBay&#39;s seladelpar an Orphan Drug in Europe for primary biliary cholangitis; shares up 2% https://seekingalpha.com/news/3294670-cymabays-seladelpar-orphan-drug-in-europe-for-primary-biliary-cholangitis-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294670-cymabays-seladelpar-orphan-drug-in-europe-for-primary-biliary-cholangitis-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294666\" data-ts=\"1505148592\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294666-gopros-big-run-continues-on-turnaround-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoPro&#39;s big run continues on turnaround optimism</a></h4><ul><li>After meeting with management, the team at Oppenheimer says it didn't hear anything new, but likes the \"grounded\" and \"realistic\" targets set by executives. The sell-siders say they're \"impressed\" with the restructuring effort.</li><li>Oppenheimer sees Hero6 likely tracking ahead of Hero5.</li><li><a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>&nbsp;<font color='green'>up 7.7%&nbsp;</font>today and about&nbsp;<font color='green'>25%</font>&nbsp;in September.</li><li>Source: Bloomberg's Brad Olesen</li></ul><div class=\"tiny-share-widget\" data-id=\"3294666\" data-linked=\"GoPro&#39;s big run continues on turnaround optimism\" data-tweet=\"$GPRO - GoPro&#39;s big run continues on turnaround optimism https://seekingalpha.com/news/3294666-gopros-big-run-continues-on-turnaround-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3294666-gopros-big-run-continues-on-turnaround-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294665\" data-ts=\"1505148579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMNP\" target=\"_blank\">IMNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294665-immune-pharma-files-for-15_6m-equity-offering-shares-down-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immune Pharma files for $15.6M equity offering; shares down 6%</a></h4><ul><li>Immune Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='red'>-5.5%</font>) slumps on average volume in apparent response to the filing of an <a href=\"https://www.sec.gov/Archives/edgar/data/1208261/000157104917007821/t1702525-s1.htm\" target=\"_blank\">S-1</a> for a $15.6M offering of 7,500 Units, consisting of Series E Convertible Preferred Stock and warrants (and common shares related to exercise of the warrants).</li><li>Each Series E share has a stated value of $1,080. Conversation price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294665\" data-linked=\"Immune Pharma files for $15.6M equity offering; shares down 6%\" data-tweet=\"$IMNP $IMNPQ - Immune Pharma files for $15.6M equity offering; shares down 6% https://seekingalpha.com/news/3294665-immune-pharma-files-for-15_6m-equity-offering-shares-down-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3294665-immune-pharma-files-for-15_6m-equity-offering-shares-down-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294663\" data-ts=\"1505148519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294663-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corp.'>TWMC</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SMIT' title='Schmitt Industries, Inc.'>SMIT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294663\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MRNS $TAHO $MARK - Midday Gainers / Losers https://seekingalpha.com/news/3294663-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3294663-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294664\" data-ts=\"1505148519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294664-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corp.'>TWMC</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SMIT' title='Schmitt Industries, Inc.'>SMIT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294664\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MRNS $TAHO $MARK - Midday Gainers / Losers https://seekingalpha.com/news/3294664-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3294664-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294662\" data-ts=\"1505148229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294662-sprouts-down-nearly-6-numbers-show-pick-up-in-whole-foods-traffic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprouts down nearly 6% as numbers show pick-up in Whole Foods traffic</a></h4><ul><li>As reported by Bloomberg, data from Foursquare Labs showed a 25% increase in traffic at Whole Foods in the first two days after the Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) purchase closed (your humble editor set foot in WFM for the first time in years last week).</li><li>The rough run continues for competitor Sprouts (<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='red'>-5.3%</font>), now&nbsp;<font color='red'>off 20%</font>&nbsp;in the last two weeks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294662\" data-linked=\"Sprouts down nearly 6% as numbers show pick-up in Whole Foods traffic\" data-tweet=\"$AMZN $AMZN $SFM - Sprouts down nearly 6% as numbers show pick-up in Whole Foods traffic https://seekingalpha.com/news/3294662-sprouts-down-nearly-6-numbers-show-pick-up-in-whole-foods-traffic?source=tweet\" data-url=\"https://seekingalpha.com/news/3294662-sprouts-down-nearly-6-numbers-show-pick-up-in-whole-foods-traffic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294661\" data-ts=\"1505147528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294661-tevas-migraine-candidate-fremanezumab-shows-significant-treatment-benefit-in-late-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva&#39;s migraine candidate fremanezumab shows significant treatment benefit in late-stage study</a></h4><ul><li>A Phase 3 clinical trial, HALO, assessing Teva Pharmaceutical Industries' (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+22.1%</font>) fremanezumab for the prevention of migraine demonstrated its efficacy for all 25 primary and secondary analyses in both monthly and quarterly dosing regimens. The results were <a href=\"https://seekingalpha.com/pr/16935974-teva-showcases-data-demonstrating-potential-fremanezumab-address-significant-unmet-need\" target=\"_blank\">presented </a>at the 18th Congress of the International Headache Society in Vancouver, Canada.</li><li>Patients with chronic migraine treated with fremanezumab experienced a statistically significant reduction in the number of migraine days of at least moderate severity compared to placebo [-4.6 days (monthly); -4.3 days (quarterly); -2.5 days placebo; p&lt;0.0001].</li><li>Other endpoints included improvements in quality-of-life and health measures, less work productivity loss and significant reductions in impairment activity outside of work.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3270722-tevas-fremanezumab-successful-late-stage-migraine-study-u-s-marketing-application-expected\" target=\"_blank\">Teva's fremanezumab successful in late-stage migraine study; U.S. marketing application expected this year; shares up 1%</a> (May 31)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294548-teva-finally-gets-new-ceo\" target=\"_blank\">Teva finally gets a new CEO</a> (Sept. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294661\" data-linked=\"Teva&#39;s migraine candidate fremanezumab shows significant treatment benefit in late-stage study\" data-tweet=\"$TEVA - Teva&#39;s migraine candidate fremanezumab shows significant treatment benefit in late-stage study https://seekingalpha.com/news/3294661-tevas-migraine-candidate-fremanezumab-shows-significant-treatment-benefit-in-late-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3294661-tevas-migraine-candidate-fremanezumab-shows-significant-treatment-benefit-in-late-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294656\" data-ts=\"1505145694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294656-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ALCO' title='Alico, Inc.'>ALCO</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294656\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NVFY $LFVN $ROX - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3294656-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3294656-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294651\" data-ts=\"1505144096\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294651-investors-not-buying-new-nordstrom-concept\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors not buying new Nordstrom concept</a></h4><ul> <li>Nordstrom (NYSE:<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>) is <font color='red'>down 4.43%</font> after unveiling plans to launch a 3K square foot concept called Nordstrom Local.</li> <li>The company plans to have dressing rooms at Nordstrom Local outlets, but will keep most of the inventory at mall-based stores or e-commerce distribution points.</li> <li>Nordstrom Local stores will also sell beverages, including wine.</li> <li>Investors aren't sure about the strategy so far.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294533-new-store-style-nordstrom\" target=\"_blank\">New store style at Nordstrom</a> (Sept. 10)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294651\" data-linked=\"Investors not buying new Nordstrom concept\" data-tweet=\"$JWN - Investors not buying new Nordstrom concept https://seekingalpha.com/news/3294651-investors-not-buying-new-nordstrom-concept?source=tweet\" data-url=\"https://seekingalpha.com/news/3294651-investors-not-buying-new-nordstrom-concept\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294645\" data-ts=\"1505142182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMMT\" target=\"_blank\">SMMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294645-summit-nabs-62m-barda-contract-for-c-diff-candidate-ridinilazole-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit nabs $62M BARDA contract for C. diff candidate ridinilazole; shares ahead 8%</a></h4><ul><li>Thinly traded micro cap Summit Therapeutics (<a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a> <font color='green'>+7.7%</font>) heads north on triple normal volume, albeit on turnover of only 41K shares, in response to its <a href=\"https://seekingalpha.com/pr/16936232-summit-awarded-barda-contract-worth-62-million-support-development-ridinilazole-treatment-c\" target=\"_blank\">announcement </a>that HHS's Biomedical Advanced Research and Development Authority &#40;BARDA&#41; has awarded it a contract valued as high as $62M to support the regulatory and clinical development of antibiotic ridinilazole for the treatment of <em>Clostridium difficile</em> (<em>C. diff</em>) infection.</li><li>Under the terms of the contract, Summit is eligible to receive $32M to support FDA approval of the protocols and commencement of enrollment in two Phase 3 clinical trials. The company is eligible for additional funding of $30M contingent on the achievement of certain milestones, including the completion of the late-stage studies and other activities related to the preparation of the NDA.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294645\" data-linked=\"Summit nabs $62M BARDA contract for C. diff candidate ridinilazole; shares ahead 8%\" data-tweet=\"$SMMT - Summit nabs $62M BARDA contract for C. diff candidate ridinilazole; shares ahead 8% https://seekingalpha.com/news/3294645-summit-nabs-62m-barda-contract-for-c-diff-candidate-ridinilazole-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3294645-summit-nabs-62m-barda-contract-for-c-diff-candidate-ridinilazole-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294640\" data-ts=\"1505141220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATI\" target=\"_blank\">ATI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294640-allegheny-gets-two-notch-upgrade-bofa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allegheny gets two-notch upgrade at BofA</a></h4><ul><li>BofA <a href=\"https://www.benzinga.com/news/17/09/10038454/bank-of-america-upgrades-allegheny-technologies-to-buy\" target=\"_blank\">raised</a> Allegheny (<a href='https://seekingalpha.com/symbol/ATI' title='Allegheny Technologies Incorporated'>ATI</a> <font color='green'>+10.2%</font>) to Buy from Underperform, with a price target of $24 vs. $16.</li><li>The company is set to benefit from a \"hefty jet engine new technology cycle\" and a shift to this end-market should see sharp engine margin improvement, while offsetting lower margin businesses.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294640\" data-linked=\"Allegheny gets two-notch upgrade at BofA\" data-tweet=\"$ATI - Allegheny gets two-notch upgrade at BofA https://seekingalpha.com/news/3294640-allegheny-gets-two-notch-upgrade-bofa?source=tweet\" data-url=\"https://seekingalpha.com/news/3294640-allegheny-gets-two-notch-upgrade-bofa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294642\" data-ts=\"1505141191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294642-risk-back-on-stocks-climb-bonds-and-gold-sink\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Risk back on - stocks climb, bonds and gold sink</a></h4><ul><li>Less-than-feared impact from Hurricane Irma and no new missile tests from N. Korea have animal spirits percolating this morning.</li><li>The Nasdaq and DJIA are&nbsp;<font color='green'>higher by 1%</font>, and the S&amp;P 500 is&nbsp;<font color='green'>up 0.8%</font>.</li><li>Alongside, gold is<font color='red'> lower by 1%</font>&nbsp;and the 10-year Treasury yield is up six basis points.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294642\" data-linked=\"Risk back on - stocks climb, bonds and gold sink\" data-tweet=\"Risk back on - stocks climb, bonds and gold sink https://seekingalpha.com/news/3294642-risk-back-on-stocks-climb-bonds-and-gold-sink?source=tweet\" data-url=\"https://seekingalpha.com/news/3294642-risk-back-on-stocks-climb-bonds-and-gold-sink\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294641\" data-ts=\"1505141174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KHC\" target=\"_blank\">KHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294641-no-second-try-from-kraft-heinz-for-unilever\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No second try from Kraft Heinz for Unilever</a></h4><ul> <li>Kraft Heinz (<a href='https://seekingalpha.com/symbol/KHC' title='The Kraft Heinz Company'>KHC</a> <font color='green'>+0.6%</font>) won't make a <a href=\"http://nypost.com/2017/09/08/kraft-heinz-no-longer-interested-in-bid-for-unilever/\" target=\"_blank\">second run</a> at acquiring Unilever (<a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a>, <a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a>), sources tell New York Post.</li> <li>The report follows up a statement made by Warrenn Buffett in August that Kraft wasn't interested in the hostile takeover path for nabbing Unilever.</li> <li>Shares of Kraft are down 6% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294641\" data-linked=\"No second try from Kraft Heinz for Unilever\" data-tweet=\"$KHC $KHC $UN - No second try from Kraft Heinz for Unilever https://seekingalpha.com/news/3294641-no-second-try-from-kraft-heinz-for-unilever?source=tweet\" data-url=\"https://seekingalpha.com/news/3294641-no-second-try-from-kraft-heinz-for-unilever\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294639\" data-ts=\"1505140818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CKPT\" target=\"_blank\">CKPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294639-checkpoint-therapeutics-ckminus-101-orphan-drug-in-u-s-for-nsclc-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Checkpoint Therapeutics&#39; CK-101 an Orphan Drug in U.S. for NSCLC; shares ahead 3%</a></h4><ul><li>Ultra-thinly traded micro cap Checkpoint Therapeutics (<a href='https://seekingalpha.com/symbol/CKPT' title='CHECKPOINT THERAPEUTICS'>CKPT</a> <font color='green'>+3.3%</font>) perks up on light volume in response to its <a href=\"https://seekingalpha.com/pr/16936451-checkpoint-therapeutics-receives-orphan-drug-designation-ckminus-101-treatment-egfr-mutation\" target=\"_blank\">announcement </a>that the FDA has designated its third-generation EGFR inhibitor <a href=\"http://www.checkpointtx.com/pipeline/ck-101-egfr-inhibitor/\" target=\"_blank\">CK-101</a> an Orphan Drug for the treatment of EGFR-positive non-small cell lung cancer &#40;NSCLC&#41;.</li><li>CK-101 is currently being evaluated in a Phase 1/2 study.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294639\" data-linked=\"Checkpoint Therapeutics&#39; CK-101 an Orphan Drug in U.S. for NSCLC; shares ahead 3%\" data-tweet=\"$CKPT - Checkpoint Therapeutics&#39; CK-101 an Orphan Drug in U.S. for NSCLC; shares ahead 3% https://seekingalpha.com/news/3294639-checkpoint-therapeutics-ckminus-101-orphan-drug-in-u-s-for-nsclc-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3294639-checkpoint-therapeutics-ckminus-101-orphan-drug-in-u-s-for-nsclc-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294638\" data-ts=\"1505140699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GT\" target=\"_blank\">GT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294638-goodyear-tire-rubber-seen-top-pick-in-auto\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goodyear Tire &amp; Rubber seen as top pick in auto</a></h4><ul> <li>Goodyear Tire &amp; Rubber (NYSE:<a href='https://seekingalpha.com/symbol/GT' title='Goodyear Tire & Rubber Co.'>GT</a>) is the <a href=\"http://www.barrons.com/articles/best-stock-in-u-s-autos-its-not-general-motors-ford-or-even-tesla-1505138708\" target=\"_blank\">top pick</a> in auto from Morgan Stanley on its view that the company is protected from the risks to the industry of EV disruption.</li> <li>The firm also points out that Goodyear doesn't face the same risks as automakers from the light vehicle credit cycle and used car pricing trends. Shares are relatively cheap at ~8X 2018 earnings estimates and 5X 2018 EBITDA, MS adds.</li> <li>Shares of Goodyear are <font color='green'>up 2.31%</font> on a decent amount of volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294638\" data-linked=\"Goodyear Tire &amp; Rubber seen as top pick in auto\" data-tweet=\"$GT - Goodyear Tire &amp; Rubber seen as top pick in auto https://seekingalpha.com/news/3294638-goodyear-tire-rubber-seen-top-pick-in-auto?source=tweet\" data-url=\"https://seekingalpha.com/news/3294638-goodyear-tire-rubber-seen-top-pick-in-auto\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294637\" data-ts=\"1505140400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLS\" target=\"_blank\">SLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294637-biovascular-withdraws-termination-notice-related-to-galenas-galeminus-401-advancement-may\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioVascular withdraws termination notice related to Galena&#39;s GALE-401, advancement may included licensing partner; shares down 3%</a></h4><ul><li>Nano cap Galena Biopharma (GALE <font color='red'>-2.9%</font>) slips on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16936254-galena-biopharma-biovascular-inc-reaffirm-galeminus-401-partnership\" target=\"_blank\">announcement </a>that licensee BioVascular has withdrawn its notice of termination and will stay the course with the development of Phase 3-stage GALE-401, although advancement could include a licensing partner if the companies decide to forego internal development.</li><li>GALE-401 is a controlled-release formulation of thrombocytosis med anagrelide (Shire's <a href=\"http://chemocare.com/chemotherapy/drug-info/agrylin.aspx\" target=\"_blank\">Agrylin</a>). Its value proposition is equivalent efficacy with less adverse side effects by virtue of its longer half-life and reduced maximum plasma concentration.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294637\" data-linked=\"BioVascular withdraws termination notice related to Galena&#39;s GALE-401, advancement may included licensing partner; shares down 3%\" data-tweet=\"$SLS - BioVascular withdraws termination notice related to Galena&#39;s GALE-401, advancement may included licensing partner; shares down 3% https://seekingalpha.com/news/3294637-biovascular-withdraws-termination-notice-related-to-galenas-galeminus-401-advancement-may?source=tweet\" data-url=\"https://seekingalpha.com/news/3294637-biovascular-withdraws-termination-notice-related-to-galenas-galeminus-401-advancement-may\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294635\" data-ts=\"1505139524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UGA\" target=\"_blank\">UGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294635-gasoline-futures-dip-to-lowest-in-two-weeks-post-irma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gasoline futures dip to lowest in two weeks post-Irma</a></h4><ul><li>\"There are a lot of people not driving,\" Mizuho's Bob Yawger tells Bloomberg. \"Irma is the gasoline story.\"</li><li>Supply isn't helping either as Harvey-related refining capacity continues to return online.</li><li><a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>&nbsp;<font color='red'>-2.75%</font>&nbsp;today, and now&nbsp;<font color='red'>off 8%</font>&nbsp;over the last five sessions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294635\" data-linked=\"Gasoline futures dip to lowest in two weeks post-Irma\" data-tweet=\"$UGA - Gasoline futures dip to lowest in two weeks post-Irma https://seekingalpha.com/news/3294635-gasoline-futures-dip-to-lowest-in-two-weeks-post-irma?source=tweet\" data-url=\"https://seekingalpha.com/news/3294635-gasoline-futures-dip-to-lowest-in-two-weeks-post-irma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294633\" data-ts=\"1505139137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTOO\" target=\"_blank\">TTOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294633-t2-bio-files-u-s-marketing-application-for-bacterial-panel-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T2 Bio files U.S. marketing application for bacterial panel; shares up 1%</a></h4><ul><li>T2 Biosystems (<a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems'>TTOO</a> <font color='green'>+0.8%</font>) <a href=\"https://seekingalpha.com/pr/16936381-t2-biosystems-submits-510-k-application-fda-review-t2bacteria-panel\" target=\"_blank\">files </a>a 510(k) application with the FDA seeking clearance to market its T2Bacterial Panel performed on its T2Dx instrument. Once approved, it will be combined with the T2Candida panel for the rapid identification of sepsis-causing pathogens.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294633\" data-linked=\"T2 Bio files U.S. marketing application for bacterial panel; shares up 1%\" data-tweet=\"$TTOO - T2 Bio files U.S. marketing application for bacterial panel; shares up 1% https://seekingalpha.com/news/3294633-t2-bio-files-u-s-marketing-application-for-bacterial-panel-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3294633-t2-bio-files-u-s-marketing-application-for-bacterial-panel-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294631\" data-ts=\"1505138807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSA\" target=\"_blank\">PSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294631-public-storage-leads-self-storage-names-lower-following-irma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Public Storage leads self-storage names lower following Irma</a></h4><ul><li>All of Public Storage's (<a href='https://seekingalpha.com/symbol/PSA' title='Public Storage'>PSA</a> <font color='red'>-2.5%</font>) Florida properties (284), and nine in So. Carolina and Georgia are temporarily closed while Irma blows through. The impact to them from the storm is not yet known.</li><li>Turning to Houston, all 116 of PSA's properties have been reopened, but seven more severely properties will have to be demolished and rebuilt.</li><li>The entire sector is in the red this session, perhaps as Irma's less-than-feared impact means less incremental demand for self-storage services.</li><li>Life Storage (<a href='https://seekingalpha.com/symbol/LSI' title='Life Storage, Inc.'>LSI</a> <font color='red'>-2.1%</font>), CubeSmart (<a href='https://seekingalpha.com/symbol/CUBE' title='CubeSmart Common Shares'>CUBE</a> <font color='red'>-2.7%</font>), Extra Space Storage (<a href='https://seekingalpha.com/symbol/EXR' title='Extra Space Storage, Inc.'>EXR</a> <font color='red'>-2.9%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294631\" data-linked=\"Public Storage leads self-storage names lower following Irma\" data-tweet=\"$PSA $PSA $LSI - Public Storage leads self-storage names lower following Irma https://seekingalpha.com/news/3294631-public-storage-leads-self-storage-names-lower-following-irma?source=tweet\" data-url=\"https://seekingalpha.com/news/3294631-public-storage-leads-self-storage-names-lower-following-irma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294630\" data-ts=\"1505138727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294630-mannkind-medical-chief-bids-adieu-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MannKind medical chief bids adieu; shares down 2%</a></h4><ul><li>MannKind (<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='red'>-2%</font>) VP, Chief Medical Officer Raymond Urbanski, M.D., Ph.D., will <a href=\"https://www.sec.gov/Archives/edgar/data/899460/000119312517281243/d414539d8k.htm\" target=\"_blank\">resign </a>effective September 29 to take a position in another company that will enable him to \"pursue his passion for oncology.\" He joined MannKind in October 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294630\" data-linked=\"MannKind medical chief bids adieu; shares down 2%\" data-tweet=\"$MNKD - MannKind medical chief bids adieu; shares down 2% https://seekingalpha.com/news/3294630-mannkind-medical-chief-bids-adieu-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3294630-mannkind-medical-chief-bids-adieu-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294629\" data-ts=\"1505138431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INVH\" target=\"_blank\">INVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294629-single-family-rental-reits-gain-following-irma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Single-family rental REITs gain following Irma</a></h4><ul><li>The sector players had seen some selling amid the Harvey wreckage and ahead of Irma, but Irma wasn't as bad as feared and investors are buying back in today.</li><li>Invitation Homes (<a href='https://seekingalpha.com/symbol/INVH' title='Invitation Homes'>INVH</a> <font color='green'>+3%</font>), American Homes 4 Rent (<a href='https://seekingalpha.com/symbol/AMH' title='American Homes 4 Rent'>AMH</a> <font color='green'>+2.7%</font>), Starwood Waypoint (<a href='https://seekingalpha.com/symbol/SFR' title='Starwood Waypoint Homes Inc'>SFR</a> <font color='green'>+3.1%</font>), Altisource Residential (<a href='https://seekingalpha.com/symbol/RESI' title='Front Yard Residential Corporation'>RESI</a> <font color='green'>+1.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294629\" data-linked=\"Single-family rental REITs gain following Irma\" data-tweet=\"$INVH $INVH $AMH - Single-family rental REITs gain following Irma https://seekingalpha.com/news/3294629-single-family-rental-reits-gain-following-irma?source=tweet\" data-url=\"https://seekingalpha.com/news/3294629-single-family-rental-reits-gain-following-irma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294627\" data-ts=\"1505138295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294627-health-insurance-innovations-under-pressure-on-bearish-report-from-sa-contributor-pearson\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations under pressure on bearish report from SA Contributor Pearson; shares down 14%</a></h4><ul><li>Health Insurance Innovations (<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-14.4%</font>) slumps on light volume in apparent response to a <a href=\"https://seekingalpha.com/article/4105714-hiiq-penalties-exceed-100-million-undisclosed-domino-effect\" target=\"_blank\">bearish outlook</a> from SA Contributor Richard Pearson that predicts that shares will plunge to $6 or below. Key points:</li><li>The company is facing fraud investigations or cease-and-desist orders in 42 states. Legal liability could exceed $100M.</li><li>Rejected for a key insurance license in home state of Florida.</li><li>Insiders have sold $50M in shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294627\" data-linked=\"Health Insurance Innovations under pressure on bearish report from SA Contributor Pearson; shares down 14%\" data-tweet=\"$HIIQ - Health Insurance Innovations under pressure on bearish report from SA Contributor Pearson; shares down 14% https://seekingalpha.com/news/3294627-health-insurance-innovations-under-pressure-on-bearish-report-from-sa-contributor-pearson?source=tweet\" data-url=\"https://seekingalpha.com/news/3294627-health-insurance-innovations-under-pressure-on-bearish-report-from-sa-contributor-pearson\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294626\" data-ts=\"1505138128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNW\" target=\"_blank\">GNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294626-genworth-gains-on-off-wall-street-recommendation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genworth gains on Off Wall Street recommendation</a></h4><ul><li>The sale of the company to China Oceanwide for $5.43 per share is likely to go through, says Off Wall Street, making Genworth (NYSE:<a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a>) a New Buy with a $5.43 price target. That's&nbsp;<font color='green'>more than 50% above</font>&nbsp;Friday's close of $3.45.</li><li>Shares today are&nbsp;<font color='green'>up 2.9%</font>&nbsp;to $3.55.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294626\" data-linked=\"Genworth gains on Off Wall Street recommendation\" data-tweet=\"$GNW - Genworth gains on Off Wall Street recommendation https://seekingalpha.com/news/3294626-genworth-gains-on-off-wall-street-recommendation?source=tweet\" data-url=\"https://seekingalpha.com/news/3294626-genworth-gains-on-off-wall-street-recommendation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294625\" data-ts=\"1505138027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAL\" target=\"_blank\">DAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294625-airline-sector-moves-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airline sector moves higher</a></h4><ul> <li>There's a solid bounce in the airline sector after the worst case scenarios on the impact of Hurricane Irma didn't occur over the weekend. Despite the sense of relief in the air, most analysts are still projecting an impact into Q4 on travel demand to the Caribbean.</li> <li>Notable gainers include major carriers Delta Air Lines (NYSE:<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a>) and American Airlines (NASDAQ:<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a>), both <font color='green'>up 1.7%</font>. JetBlue (NASDAQ:<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a>) and SkyWest SKYW (NASDAQ:<a href='https://seekingalpha.com/symbol/SKYW' title='SkyWest, Inc.'>SKYW</a>) are <font color='green'>2.0% higher</font> in early trading.</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/JETS' title='U.S. Global Jets ETF'>JETS</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294625\" data-linked=\"Airline sector moves higher\" data-tweet=\"$DAL $DAL $AAL - Airline sector moves higher https://seekingalpha.com/news/3294625-airline-sector-moves-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3294625-airline-sector-moves-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294624\" data-ts=\"1505137409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNN\" target=\"_blank\">RNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294624-rexahn-pharma-updates-on-pipeline-candidates-supinoxin-and-rxminus-3117-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rexahn Pharma updates on pipeline candidates Supinoxin and RX-3117; shares ahead 6%</a></h4><ul><li>Thinly traded nano cap Rexahn Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='green'>+5.7%</font>) jumps out the gate this morning after the company <a href=\"https://seekingalpha.com/pr/16936426-rexahn-pharmaceuticals-presents-final-data-supinoxin-phase-clinical-study-new-preclinical\" target=\"_blank\">announced </a>updated data on pipeline candidates Supinoxin and RX-3117 at ESMO in Madrid.</li><li>Phase 1 results on Supinoxin, an orally available small molecule inhibitor of phosphorylated-p68 (P-p68), showed it to be safe and well-tolerated at 250 mg once daily for five days on, two days off for four consecutive weeks, the selected regimen for a Phase 2a study, initiated in February, in patients with metastatic triple negative breast cancer who have failed multiple prior lines of chemo.</li><li>Preclinical data on RX-3117, in combination with Celgene's Abraxane (nab-paclitaxel), showed effectiveness in a pancreatic cancer model and an additive effect with Abraxane. A Phase 2 study in newly diagnosed pancreatic cancer patients is next. RX-3317, an orally available small molecule nucleoside compound, also showed a treatment effect in preclinical models when combined with a checkpoint inhibitor. It has Orphan Drug status in the U.S. for pancreatic cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294624\" data-linked=\"Rexahn Pharma updates on pipeline candidates Supinoxin and RX-3117; shares ahead 6%\" data-tweet=\"$RNN $REXN - Rexahn Pharma updates on pipeline candidates Supinoxin and RX-3117; shares ahead 6% https://seekingalpha.com/news/3294624-rexahn-pharma-updates-on-pipeline-candidates-supinoxin-and-rxminus-3117-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3294624-rexahn-pharma-updates-on-pipeline-candidates-supinoxin-and-rxminus-3117-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294620\" data-ts=\"1505136579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294620-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='green'>+42%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16936059-guatemalan-supreme-court-reinstates-escobal-license\" target=\"_blank\">reinstating</a> the Escobal mining license of Tahoe's Guatemalan subsidiary,&nbsp;Minera San Rafael.</li>     <li><a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+43%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16936283-marinus-announces-successful-clinical-trial-results-declares-cdkl5-disorder-lead-pediatric\" target=\"_blank\">top-line data</a> from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial.</li>     <li><a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='green'>+22%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='green'>+18%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/LINU-OLD' title='LiNiu Technology Group'>LINU-OLD</a> <font color='green'>+14%</font>&nbsp;on three-year strategic cooperation <a href=\"https://seekingalpha.com/pr/16936455-liniu-technology-group-announces-strategic-cooperation-agreement-peoples-insurance-company\" target=\"_blank\">agreement</a> with The Peoples Insurance Company of&nbsp;China&nbsp;Limited&rsquo;s.</li>     <li><a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='green'>+14%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='green'>+14%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+14%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16936426-rexahn-pharmaceuticals-presents-final-data-supinoxin-phase-clinical-study-new-preclinical\" target=\"_blank\">announced</a> that final data on the Supinoxin&trade; Phase I clinical study in solid tumors were presented at the 2017 European Society for Medical Oncology (ESMO) Congress.</li>     <li><a href='https://seekingalpha.com/symbol/RIC' title='Richmont Mines, Inc'>RIC</a> <font color='green'>+10%</font>&nbsp;on being <a href=\"https://seekingalpha.com/pr/16936193-alamos-gold-announces-friendly-acquisition-richmont-mines\" target=\"_blank\">acquired</a> by Richmont Mines.</li>     <li><a href='https://seekingalpha.com/symbol/AHL' title='Aspen Insurance Holdings Limited'>AHL</a> <font color='green'>+9%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a> <font color='green'>+7%</font>&nbsp;on treatment effect in certain lung cancer patients in early-stage study.</li>     <li><a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294595-array-bios-binimetinib-encorafenib-combo-extends-progression-free-survival-certain-advanced\" target=\"_blank\">announcement</a> of binimetinib/encorafenib combo extends progression-free survival in certain advanced melanoma patients in late-stage study.</li>     <li><a href='https://seekingalpha.com/symbol/CRNT' title='Ceragon Networks Ltd.'>CRNT</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='green'>+6%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3294513-kemet-plus-1_7-percent-pricing-secondary-share-offering\" target=\"_blank\">pricing</a> secondary share offering.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294620\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$TAHO $MRNS $IDRA - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3294620-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3294620-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294618\" data-ts=\"1505136172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294618-grubhubminus-1_5-credit-suisse-heads-to-sideline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub -1.5% as Credit Suisse heads to sideline</a></h4><ul>   <li>GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a>) is <font color='red'>off 1.5%</font> premarket after a cut to Neutral at Credit Suisse following a solid 2017 so far.</li>    <li>The firm had rated the food-delivery specialist at Outperform.</li>    <li>It's raised its price target to $53, though, cutting implied downside to 5.5%.</li>    <li>GrubHub is <font color='green'>up 29.4%</font> in the past three months, and <font color='green'>up 66%</font> over the past six months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294618\" data-linked=\"GrubHub -1.5% as Credit Suisse heads to sideline\" data-tweet=\"$GRUB - GrubHub -1.5% as Credit Suisse heads to sideline https://seekingalpha.com/news/3294618-grubhubminus-1_5-credit-suisse-heads-to-sideline?source=tweet\" data-url=\"https://seekingalpha.com/news/3294618-grubhubminus-1_5-credit-suisse-heads-to-sideline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294617\" data-ts=\"1505136145\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RXDX\" target=\"_blank\">RXDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294617-ignytas-rxdxminus-105-shows-treatment-effect-in-certain-lung-cancer-patients-in-early-stage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ignyta&#39;s RXDX-105 shows treatment effect in certain lung cancer patients in early-stage study; shares ahead 7% premarket</a></h4><ul><li>Ignyta (NASDAQ:<a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16936327-ignyta-provides-update-entrectinib-rxdxminus-105-esmo-2017-congress\" target=\"_blank\">announcement </a>of positive data from a Phase 1b clinical trial assessing RXDX-105 in a rare subpopulation of non-small cell lung cancer &#40;NSCLC&#41; patients with genetic mutations called <a href=\"https://ignyta.com/providers/rx-precision-medicine-pipeline/ret-fusions/\" target=\"_blank\">RET fusions</a>. The results were presented as ESMO in Madrid.</li><li>The preliminary response rate was 75% in RET inhibitor-naive NSCLC RET fusion-positive patients (n=8), including six partial responders. Median duration of response has net been reached.</li><li>The company says it will complete the study with no additional enrollment. It will continue to discuss RXDX-105 will potential development partners and will update investors in H1 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293797-ignyta-track-h2-2018-nda-filing-lung-cancer-med-entrectinib-shares-11-percent-premarket\" target=\"_blank\">Ignyta on track for H2 2018 NDA filing for lung cancer med entrectinib; shares down 11% premarket</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294617\" data-linked=\"Ignyta&#39;s RXDX-105 shows treatment effect in certain lung cancer patients in early-stage study; shares ahead 7% premarket\" data-tweet=\"$RXDX - Ignyta&#39;s RXDX-105 shows treatment effect in certain lung cancer patients in early-stage study; shares ahead 7% premarket https://seekingalpha.com/news/3294617-ignytas-rxdxminus-105-shows-treatment-effect-in-certain-lung-cancer-patients-in-early-stage?source=tweet\" data-url=\"https://seekingalpha.com/news/3294617-ignytas-rxdxminus-105-shows-treatment-effect-in-certain-lung-cancer-patients-in-early-stage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294613\" data-ts=\"1505135472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294613-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>&nbsp;<font color='red'>-23%</font>&nbsp;after Janssen backs out of hep C <a href=\"https://seekingalpha.com/news/3294566-achillion-10-percent-premarket-janssen-backs-hep-c-collaboration\" target=\"_blank\">collaboration</a>.</li><li><a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294594-alamos-gold-acquires-richmont-mines\" target=\"_blank\">acquiring</a> Richmont Mines.</li><li><a href='https://seekingalpha.com/symbol/ICL' title='Israel Chemicals Ltd.'>ICL</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16936067-eldorado-gold-announces-amended-investment-plans-greece\" target=\"_blank\">announcing</a> amended investment plans in Greece.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294613\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$ACHN $AGI $ICL - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3294613-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3294613-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294606\" data-ts=\"1505134328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXE\" target=\"_blank\">NXE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294606-nexgen-acquires-remaining-stake-in-dufferin-lake-property\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NexGen acquires remaining stake in Dufferin Lake property</a></h4><ul> <li>NexGen Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/NXE' title='Nexgen Energy Ltd.'>NXE</a>) buys out the remaining 40% stake from Rainmaker Resources and Eagle Trail Properties in the Dufferin Lake property.</li><li>Upon closing of the transaction, the company will hold a 100% interest in the property.</li><li>NexGen will issue 83.33K shares to Eagle Trail Properties and 27.78K shares to Rainmaker Resources in consideration for the asset.</li><li>The transactions rep an aggregate of $320K of shares at a deemed price of $2.88 per share</li> <li>The acquisition is expected to close on or about September 18.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16936184-nexgen-acquires-remaining-40-percent-interest-dufferin-lake-property\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3294606\" data-linked=\"NexGen acquires remaining stake in Dufferin Lake property\" data-tweet=\"$NXE - NexGen acquires remaining stake in Dufferin Lake property https://seekingalpha.com/news/3294606-nexgen-acquires-remaining-stake-in-dufferin-lake-property?source=tweet\" data-url=\"https://seekingalpha.com/news/3294606-nexgen-acquires-remaining-stake-in-dufferin-lake-property\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294604\" data-ts=\"1505134079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRNS\" target=\"_blank\">MRNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294604-marinus-pharmas-ganaxolone-shows-treatment-effect-in-mid-stage-study-in-rare-seizure-disorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marinus Pharma&#39;s ganaxolone shows treatment effect in mid-stage study in rare seizure disorder; shares ahead 28% premarket</a></h4><ul><li>Nano cap Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a>) is up&nbsp;<font color='green'>28%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16936283-marinus-announces-successful-clinical-trial-results-declares-cdkl5-disorder-lead-pediatric\" target=\"_blank\">announcement </a>of positive top-line data from an open-label Phase 2 study assessing Orphan Drug-tagged ganaxolone in patients with <a href=\"https://www.cdkl5.com/about-cdkl5/faqs/\" target=\"_blank\">CDKL5</a>, a rare X-linked neurological disorder characterized by seizures that begin in an infant's early life.</li><li>Patients received up the 1,800 mg/day of oral ganaxolone, in addition to their current therapy, for up to 26 weeks. In the intent-to-treat group, the median decrease in 28-day seizure frequency was 43% (n=7) while the median increase from baseline in seizure-free days was 78% (n=5).</li><li>The data will be submitted for presentation at a future medical conference and for publication.</li><li>The company plans to advance ganaxolone into Phase 3 development for the indication.</li><li>The company will host a conference call this morning at 9:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294604\" data-linked=\"Marinus Pharma&#39;s ganaxolone shows treatment effect in mid-stage study in rare seizure disorder; shares ahead 28% premarket\" data-tweet=\"$MRNS - Marinus Pharma&#39;s ganaxolone shows treatment effect in mid-stage study in rare seizure disorder; shares ahead 28% premarket https://seekingalpha.com/news/3294604-marinus-pharmas-ganaxolone-shows-treatment-effect-in-mid-stage-study-in-rare-seizure-disorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3294604-marinus-pharmas-ganaxolone-shows-treatment-effect-in-mid-stage-study-in-rare-seizure-disorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294601\" data-ts=\"1505133958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294601-cruise-line-stocks-head-to-higher-ground\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cruise line stocks head to higher ground</a></h4><ul> <li>Carnival (NYSE:<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a>) is <font color='green'>up 2.2%</font> in premarket trading and Royal Caribbean (NYSE:<a href='https://seekingalpha.com/symbol/RCL' title='Royal Caribbean Cruises Ltd.'>RCL</a>) is <font color='green'>1.1% higher</font> as the cruise line stocks recover some ground lost last week ahead of Hurricane Irma.</li> <li>Susquehanna reminds that travel demand tends to bounce back quick after Caribbean hurricanes.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3294601\" data-linked=\"Cruise line stocks head to higher ground\" data-tweet=\"$CCL $CCL $RCL - Cruise line stocks head to higher ground https://seekingalpha.com/news/3294601-cruise-line-stocks-head-to-higher-ground?source=tweet\" data-url=\"https://seekingalpha.com/news/3294601-cruise-line-stocks-head-to-higher-ground\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294598\" data-ts=\"1505133199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294598-jefferies-downgrades-seagate-technology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies downgrades Seagate Technology</a></h4><ul><li>        Seagate Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) shares&nbsp;<font color='red'>down 2.25%</font>&nbsp;premarket after a Jefferies downgrade from Buy to Hold with the price target slashed from $40 to $29.</li><li>               Analyst James Kisner says channel checks show Seagate could still struggle with 10TB helium drive ramping.&nbsp;</li><li>               Kisner notes that the company&rsquo;s lack of clear NAND strategy makes it now fully exposed to any HDD market accelerations from constricted NAND supplies.&nbsp;</li><li>                  FY17 EPS estimate at $4.12 and FY18 EPS estimate dropped from $3.54 to $3.16.    </li><li>               Source: <a href=\"https://www.streetinsider.com/Analyst+Comments/Jefferies+Downgrades+Seagate+Technology+%28STX%29+to+Hold/13281609.html\" target=\"_blank\">StreetInsider</a> &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3294598\" data-linked=\"Jefferies downgrades Seagate Technology\" data-tweet=\"$STX - Jefferies downgrades Seagate Technology https://seekingalpha.com/news/3294598-jefferies-downgrades-seagate-technology?source=tweet\" data-url=\"https://seekingalpha.com/news/3294598-jefferies-downgrades-seagate-technology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294595\" data-ts=\"1505132617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294595-array-bios-binimetinib-encorafenib-combo-extends-progression-free-survival-in-certain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array Bio&#39;s binimetinib/encorafenib combo extends progression-free survival in certain advanced melanoma patients in late-stage study; shares ahead 7% premarket</a></h4><ul><li>Array BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16935982-phase-3-columbus-part-2-results-braf-mutant-melanoma-presented-european-society-medical\" target=\"_blank\">announcement </a>of positive data from the second part of a Phase 3 clinical trial, COLUMBUS, assessing binimetinib (45 mg twice daily) and encorafenib (300 mg once daily) (COMBO300) in patients with BRAF-positive advanced, unresectable/metastatic melanoma. The results were presented at ESMO in Madrid.</li><li>Median progression-free survival &#40;PFS&#41; in the treatment group was 12.9 months compared to 9.2 months for patients receiving encorafenib alone with 23% less risk of cancer progression or death (hazard ratio: 0.77).</li><li>In July, the company submitted two NDAs to the FDA seeking approval of COMBO450 (binimetinib 45 mg twice daily + encorafenib 450 mg once daily) for the treatment of patients with BRAF-positive advanced, unresectable/metastatic melanoma.</li><li>Part 2 of <a href=\"https://clinicaltrials.gov/ct2/show/NCT01909453?term=NCT01909453&amp;rank=1\" target=\"_blank\">COLUMBUS </a>was specifically designed to assess the contribution of binimetinib by reducing the dose of encorafenib to 300 mg in the combo arm.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294461-array-bios-binimetinib-encorafenib-show-encouraging-treatment-effect-initial-phase-late-stage\" target=\"_blank\">Array Bio's binimetinib and encorafenib show encouraging treatment effect in initial phase of late-stage study in treatment-resistant colorectal cancer; shares ahead 17%</a> (Sept. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294595\" data-linked=\"Array Bio&#39;s binimetinib/encorafenib combo extends progression-free survival in certain advanced melanoma patients in late-stage study; shares ahead 7% premarket\" data-tweet=\"$ARRY - Array Bio&#39;s binimetinib/encorafenib combo extends progression-free survival in certain advanced melanoma patients in late-stage study; shares ahead 7% premarket https://seekingalpha.com/news/3294595-array-bios-binimetinib-encorafenib-combo-extends-progression-free-survival-in-certain?source=tweet\" data-url=\"https://seekingalpha.com/news/3294595-array-bios-binimetinib-encorafenib-combo-extends-progression-free-survival-in-certain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294589\" data-ts=\"1505132064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294589-treasurys-pull-back-alongside-market-fears\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Treasurys pull back alongside market fears</a></h4><ul><li>Hurricane Irma caused plenty of damage and millions are without power, but its punch was <a href=\"https://seekingalpha.com/news/3294578-big-day-insurers-tap-irma-less-feared\" target=\"_blank\">far less than feared</a>.</li><li>Stocks are poised to open about half-a-percent higher, and the 10-year Treasury yield - which threatened to dip below 2% last week - is all the way up to 2.10%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a><font color='red'> -0.55%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='green'>+1.1%</font>&nbsp;premarket</li><li>The FOMC's two-day September meeting begins a week from Tuesday, and markets have priced out the chance of any rate hike then.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294589\" data-linked=\"Treasurys pull back alongside market fears\" data-tweet=\"$TLT $TBT - Treasurys pull back alongside market fears https://seekingalpha.com/news/3294589-treasurys-pull-back-alongside-market-fears?source=tweet\" data-url=\"https://seekingalpha.com/news/3294589-treasurys-pull-back-alongside-market-fears\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294583\" data-ts=\"1505131214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLSE\" target=\"_blank\">PLSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294583-trading-in-pulse-biosciences-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading in Pulse Biosciences halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Pulse Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a>) pending the release of news.</li><li>Pulse's technology platform is called&nbsp;<a href=\"http://www.pulsebiosciences.com/nano-pulse-stimulation/\" target=\"_blank\">Nano-Pulse Stimulation</a>&nbsp;&#40;NPS&#41;. The company says NPS has potential as a cancer treatment. When NPS is applied directly to tissue it creates a transient opening of small pores in cell and organelle membranes that triggers a signaling cascade within a tumor that leads to cell death.</li><li><strong>Update</strong>: The company <a href=\"https://seekingalpha.com/pr/16936347-pulse-biosciences-announces-withdrawal-planned-resubmission-510-k-application-pulsetxtm\" target=\"_blank\">announced </a>that it has withdrawn its U.S. 510(k) application for the PulseTx System due to the FDA's request for additional data that it could not provide within the 90-day review period. The filing will be resubmitted in the coming months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294583\" data-linked=\"Trading in Pulse Biosciences halted pending news\" data-tweet=\"$PLSE - Trading in Pulse Biosciences halted pending news https://seekingalpha.com/news/3294583-trading-in-pulse-biosciences-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3294583-trading-in-pulse-biosciences-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294580\" data-ts=\"1505130942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDRA\" target=\"_blank\">IDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294580-idera-pharmas-imominus-2125-shows-encouraging-action-in-early-stage-melanoma-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Idera Pharma&#39;s IMO-2125 shows encouraging action in early-stage melanoma study; shares ahead 15% premarket</a></h4><ul><li>Idera Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a>) is up&nbsp;<font color='green'>15%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16936017-idera-pharmaceuticals-presents-positive-phase-1-data-intratumoral-imominus-2125-combination\" target=\"_blank\">announcement </a>of positive data in a Phase 1 clinical trial assessing IMO-2125, combined with Bristol-Myers Squibb's YERVOY (ipilimumab), in patients with treatment-resistant melanoma. The data were presented at ESMO in Madrid.</li><li>The dose selection process involved 18 patients, 17 of whom progressed after receiving Bristol-Myers' OPDIVO (nivolumab) or Merck's KEYTRUDA (pembrolizumab). Six of nine patients who received the recommended Phase 2 dose of 8 mg of IMO-2125 experienced disease control, including one complete responder and three partial responders.</li><li>The IMO-2125/YERVOY combination was tolerable at all doses studied.</li><li>The target number of patients has been expanded in the ongoing Phase 2 expansion to include patients who have received prior treatment with YERVOY.</li><li>A Phase 3 study in PD-1-refractory melanoma will commence in Q1 2018.</li><li>IMO-2125 is an agonist of endosomal Toll-like receptor &#40;TLR&#41; 9, a cell surface protein that plays a key role in pathogen recognition and innate immunity.</li><li>The company will host a webcast this morning at 9:00 am ET to discuss the results.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275272-ideras-imominus-2125-orphan-drug-u-s-advanced-melanoma-shares-ahead-5-percent-premarket\" target=\"_blank\">Idera's IMO-2125 an Orphan Drug in U.S. for advanced melanoma; shares ahead 5% premarket</a> (June 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3294580\" data-linked=\"Idera Pharma&#39;s IMO-2125 shows encouraging action in early-stage melanoma study; shares ahead 15% premarket\" data-tweet=\"$IDRA - Idera Pharma&#39;s IMO-2125 shows encouraging action in early-stage melanoma study; shares ahead 15% premarket https://seekingalpha.com/news/3294580-idera-pharmas-imominus-2125-shows-encouraging-action-in-early-stage-melanoma-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3294580-idera-pharmas-imominus-2125-shows-encouraging-action-in-early-stage-melanoma-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294575\" data-ts=\"1505130251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294575-tesla-adds-driving-range-for-owners-escaping-irma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla adds driving range for some owners escaping Irma</a></h4><ul> <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) sent a free update to some owners in Florida to help them extend their driving range ahead of Hurricane Irma.</li> <li>The update unlocked the full battery potential of Model S/X 60/60D vehicles with 75 kWh battery packs, according to <a href=\"https://electrek.co/2017/09/09/tesla-extends-range-vehicles-for-free-in-florida-escape-hurricane-irma/\" target=\"_blank\">Electrek</a>.</li> <li>Tesla <a href=\"https://teslamotorsclub.com/blog/2017/09/10/tesla-remotely-extends-range-to-help-owners-escape-hurricane-irma/\" target=\"_blank\">note</a> to select owners: \"Due to these exceptional circumstances, and to help you better prepare to evacuate and get to safety, your vehicle has been adjusted at no cost to you to temporarily access the additional battery capacity until September 16th.\"</li> <li>TSLA <font color='green'>+2.01%</font> premarket to $350.30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3294575\" data-linked=\"Tesla adds driving range for some owners escaping Irma\" data-tweet=\"$TSLA - Tesla adds driving range for some owners escaping Irma https://seekingalpha.com/news/3294575-tesla-adds-driving-range-for-owners-escaping-irma?source=tweet\" data-url=\"https://seekingalpha.com/news/3294575-tesla-adds-driving-range-for-owners-escaping-irma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>235&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294573\" data-ts=\"1505129900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294573-contravir-pharmaceuticals-receives-hbv-ind-approval-for-tenofovir-exalidex-in-u-s-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir Pharmaceuticals receives HBV IND approval for Tenofovir Exalidex in the U.S.; shares ahead 38% premarket</a></h4><ul> <li>FDA has <a href=\"https://seekingalpha.com/pr/16936155-contravir-pharmaceuticals-receives-hbv-ind-approval-tenofovir-exalidex-txl-united-states\" target=\"_blank\">approved</a> ContraVir Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) Investigational New Drug &#40;IND&#41; Application in the U.S. for its lead HBV compound, <a href=\"https://contravir.com/txl/\" target=\"_blank\">TXL</a> for the treatment of chronic hepatitis B.</li>   <li>Earlier this year, ContraVir completed a Phase 1 and a Phase 2a, 28 day study in HBV-infected patients in Thailand. Having successfully achieved proof-of-concept, ContraVir intends to expand the TXL clinical program and initiate its first US-based clinical trial for TXL in Q4, pending approval by the Institutional Review Board in patients with severe renal impairment.</li><li>Tenofovir exalidex &#40;TXL&#41; is a highly potent prodrug of the antiviral tenofovir.&nbsp; Tenofovir is the active component of both Vemlidy (tenofovir alafenamide) and Viread (tenofovir disoproxil fumarate).</li><li>Shares are up&nbsp;<font color='green'>38%</font>&nbsp;premarket on light volume.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3294573\" data-linked=\"ContraVir Pharmaceuticals receives HBV IND approval for Tenofovir Exalidex in the U.S.; shares ahead 38% premarket\" data-tweet=\"$CTRV $HEPA - ContraVir Pharmaceuticals receives HBV IND approval for Tenofovir Exalidex in the U.S.; shares ahead 38% premarket https://seekingalpha.com/news/3294573-contravir-pharmaceuticals-receives-hbv-ind-approval-for-tenofovir-exalidex-in-u-s-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3294573-contravir-pharmaceuticals-receives-hbv-ind-approval-for-tenofovir-exalidex-in-u-s-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294566\" data-ts=\"1505128550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHN\" target=\"_blank\">ACHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294566-achillion-down-10-premarket-after-janssen-backs-out-of-hep-c-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achillion down 10% premarket after Janssen backs out of hep C collaboration</a></h4><ul><li>Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) slips&nbsp;<font color='red'>10%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16936110-achillion-announces-termination-worldwide-collaboration-hepatitis-c-janssen\" target=\"_blank\">announcement </a>that Johnson &amp; Johnson's (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) Janssen Pharmaceuticals has terminated their global license and collaboration agreement related to hepatitis C and has stopped development of JNJ-4178, a combination of three direct-acting antivirals: AL-335, odalasvir and simeprevir.</li><li>CEO Milind Deshpande, Ph.D., says,&nbsp;&ldquo;We are disappointed by Janssen's decision to discontinue HCV development given the positive data presented in phase 2a with JNJ-4178, demonstrating a 100% cure rate &nbsp;after only six weeks of therapy. While we believe that patients worldwide would benefit from convenient, short-duration therapies like JNJ-4178, we remain fully focused on advancing our factor D portfolio of complement alternative pathway inhibitors in areas where patient needs are greatest, and using our strong balance sheet of almost $370 million in cash and cash equivalents at June 30, 2017 to do so.\"</li><li>Management will host a conference call this morning at 9:00 am ET to discuss its plans.</li></ul><div class=\"tiny-share-widget\" data-id=\"3294566\" data-linked=\"Achillion down 10% premarket after Janssen backs out of hep C collaboration\" data-tweet=\"$ACHN $ACHN $JNJ - Achillion down 10% premarket after Janssen backs out of hep C collaboration https://seekingalpha.com/news/3294566-achillion-down-10-premarket-after-janssen-backs-out-of-hep-c-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3294566-achillion-down-10-premarket-after-janssen-backs-out-of-hep-c-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3294548\" data-ts=\"1505118757\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3294548-teva-finally-gets-new-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva finally gets a new CEO</a></h4><ul><li>Ending months of speculation over who will lead the drugmaker, <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> has <a href=\"https://www.wsj.com/articles/teva-names-kare-schultz-as-new-chief-executive-1505115189\" target=\"_blank\">named</a> Kare Schultz as its new chief executive as it struggles under the weight of an acquisition streak, generic competition and tough pricing environment.</li><li>The healthcare veteran joins the company with about 30 years of experience in the industry, most recently serving as CEO of Denmark&rsquo;s H. Lundbeck (<a href='https://seekingalpha.com/symbol/HLUYY' title='H. Lundbeck A/S ADR'>OTCPK:HLUYY</a>).</li><li>TEVA<font color='green'> +7.4%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3294548\" data-linked=\"Teva finally gets a new CEO\" data-tweet=\"$TEVA $TEVA $HLUYY - Teva finally gets a new CEO https://seekingalpha.com/news/3294548-teva-finally-gets-new-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3294548-teva-finally-gets-new-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":68,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}